Paclitaxel 300mg/50mL
        
            
            
                | Product Overview | 
                        | Generic Name | Paclitaxel 300mg/50mL | 
                                    | Brand Name(s) | Taxol, Pacliltax, Nanoxel, Z-Taxel, Altaxel, Plaxel | 
                                    | Form | Concentrate for infusion (vial) | 
                                    | Strength | 300 mg/50 mL (6 mg/mL | 
                                    | Therapeutic Class | Microtubule inhibitor (taxane class) | 
                                    | ATC Code | L01CD01 | 
            
            
            
                | Manufacturing & Regulatory | 
                        | Manufacturer | Fresenius Kabi (Nanoxel), Aetos, Biogen, Cipla | 
                                    | Country | India/EU | 
                                    | GMP Compliance | WHO-GMP | 
                                    | DMF/CEP | Manufacturer-specific, not public | 
                                    | COFEPRIS | Under Registration (2025) | 
                                    | Free Sale Certificate | Yes | 
            
            
            
                | Logistics & Export | 
                        | MOQ | 25 Vials | 
                                    | Shelf Life | 24 Months | 
                                    | Storage | Store below 25 °C, protect from light | 
                                    | Incoterms | EXW/FOB/CIF negotiable | 
                                    | Lead Time | 10 Days | 
            
            
            
                | Documentation | 
                        | Certificate of Analysis (COA) | Certificate of Analysis likely provided on purchase; not publicly posted | 
                                    | SDS | Upon Request, not publicly posted | 
                                    | CTD Summary | proprietary; may be available upon commercial commitment/documentation fee | 
            
        
                    
                
Description
                Indications & Usage: Paclitaxel is indicated—often with platinum chemotherapy—for treatment of ovarian, breast, lung (NSCLC), pancreatic cancers, Kaposi's sarcoma, cervical cancer . It stabilizes microtubules to inhibit cell division. Pre‑medication with corticosteroids, antihistamines, H2 antagonists is required due to hypersensitivity risk            
        
       
            Request for Quote